Letter to the Editor,

There is an urgent need to understand the pathogenesis of severe acute respiratory syndrome - Coronavirus -2 (SARS-CoV-2) infection. Recent reports suggest that SARS-CoV-2 fails to induce significant amounts of interferon (IFN) in tumour tissue explant cultures \[[@bib0005]\] and in *in vitro* cell and animal models \[[@bib0010]\], the latter specifying that IFN expression may however be obtained at high multiplicity of infection. Since IFNs are known to play a key role in the response to viral infections, the aforementioned low ability of SARS-CoV-2 to induce all IFN types is significant from a pathogenetic point of view and such failure may be one of the keys to explaining the pathogenesis of COVID-19. Indeed, it has been proposed that the lack of induction of significant amounts of all types of IFN may influence the kinetics of SARS-CoV-2 load in nasopharyngeal secretions \[[@bib0005]\], possibly explaining the high transmissibility of the infection, and that a reduced innate antiviral defence is associated with elevated inflammatory cytokine production \[[@bib0010]\]. The above data has led to the conclusion that the use of exogenous IFN to stimulate antiviral immunity might be successful for treating SARS-CoV-2 infection \[[@bib0015]\]. All the above results await interpretation from the perspective of infection pathophysiology, considering the recent finding on IFN-induced expression of ACE2 receptor \[[@bib0020]\].

It is our firm opinion, however, that further observation is required before drawing general conclusions about the lack of induction and production of IFNs in SARS-CoV-2 infection.

Indeed, in the framework of a project addressing the pathogenesis of the SARS-CoV-2 infection, we were able to detect type I IFN genes (IFN alpha and omega), but not type II IFN genes (IFN-gamma), in pelleted cells from oropharyngeal and/or nasopharyngeal swabs of COVID-19 patients hospitalized at Sapienza University Hospital "Policlinico Umberto I" in Rome, Italy.

Specifically (see [Table 1](#tbl0005){ref-type="table"} and the relative methods), type I IFN genes were detected in 47 out of 50 patients who were COVID-19-diagnosed by RT-PCR (RealStar® SARS-CoV-2 Altona Diagnostic -- Germany) after RNA extraction (QIAamp® Viral RNA - Qiagen) of samples taken from oropharyngeal and/or nasopharyngeal swabs. The producing cells have not been characterized, but we believe that the data have added value since they were obtained in ex vivo experiments directly from COVID-19 patients and not from experiments performed on explanted tumour cells \[[@bib0005]\] or on cellular lines/animal model \[[@bib0010]\].Table 1Level of type I and II Interferon (IFN) measured in respiratory swabs of COVID-19 patients (n = 50).Table 1GenesCt \<40[\*](#tblfn0005){ref-type="table-fn"}%2^−ΔΔCt^[\*\*](#tblfn0010){ref-type="table-fn"}IFN-alpha47/5094.04.13 (1.22--31.29)IFN-omega47/5094.07.92 (1.30--219.18)IFN-gamma0/50NANA[^1][^2]

Although we do not currently know whether or what type or subtypes of IFN are produced in respiratory secretions and whether the IFNs subtypes we have detected display a beneficial or detrimental effect on the natural history of COVID-19 \[[@bib0025]\], we strongly believe that, in light of the data or comments recently reported by Chun \[[@bib0005]\], Blanco-Melo D \[[@bib0010]\], and O'Brien \[[@bib0015]\] and the number of active clinical treatment trials with IFNs now underway \[[@bib0030]\], it is urgent and critically important to deliver data indicating that an IFN response (at least type I IFN) does exist in the respiratory tract of SARS-CoV-2-infected patients.
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[^1]: Data are expressed as number (percentage) of COVID-19 patients (n = 50) with Ct values lower than 40.

[^2]: IFN expression data were calculated using 2^−ΔΔCt^ method. Each IFN raw Ct value was tagged as undetermined when fell between levels of 40 and 45. Raw Ct values were normalized using the endogenous control (β-glucuronidase) according to the equation: ΔCtIFN = CtIFN - CtGUS. Differences between patients and healthy donors (n = 10) were calculated based on the ΔΔCt measure, where ΔΔCtIFN = ΔCtSARS-CoV-2 -- mean (ΔCtHealthyDonors). Expression of IFNs and housekeeping genes mRNAs were evaluated using RT/Real Time PCR \[[@bib0035]\]. Data are expressed as median (range).
